NAT10 and prostate cancer: To further clarify whether NAT10 inhibition still affected castration-resistant prostate cancer cells, AR-positive VCaP cells were subjected to one week of short-term treatment with ADT, DHT, and enzalutamide, and the growth of these cells in the presence of Remodelin (20 μM) was analyzed.